FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Chemomab Therapeutics Ltd. Stock AnalysisComprehensive stock analysis for Chemomab Therapeutics Ltd. (CMMB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCMMB
CMMB
Chemomab Therapeutics Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CMMB
Home🔹Stocks🔹Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd.

CMMB•NASDAQ

Chemomab Therapeutics Ltd.

CMMB•NASDAQ
Market cap
$8.80M
Sentiment

Your view on CMMB

Mkt Cap
$8.80M
Sentiment
Your view
CMMB
Chemomab Therapeutics Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CMMB
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Chemomab Therapeutics Ltd.

Industry
Biotechnology
Sector
Healthcare
CEO
Adi Mor George
Headquarters
Building 7, Tel Aviv, IL
Industry
Biotechnology
Sector
Healthcare
CEO
Adi Mor George
Headquarters
Building 7, Tel Aviv, IL
Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News